Severe radiation dermatitis in patients with locally advanced head and neck cancer treated with concurrent radiation and cetuximab

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 32, Issue 5, 2009, Pages 472-476

  Koutcher, Lawrence D ^a   Wolden, Suzanne ^a   Lee, Nancy ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cetuximab; Chemoradiation; Complications; Dermatitis; Locally advanced head and neck cancer

Indexed keywords

CETUXIMAB; PACLITAXEL;

ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; DISEASE SEVERITY; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; OROPHARYNX CARCINOMA; RADIATION DERMATITIS; RADIATION FIELD; SKIN BLEEDING; SKIN CARE; SKIN NECROSIS; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; TONSIL CARCINOMA; TUMOR BIOPSY;

AGED; ANTIBODIES, MONOCLONAL; CHEMORADIOTHERAPY; HEAD AND NECK NEOPLASMS; HUMANS; MALE; RADIODERMATITIS; RETROSPECTIVE STUDIES;

EID: 70350654255     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e318193125c     Document Type: Article

References (31)

1. The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991;324:1685-1690.
2. Lefebvre JL, Chevalier D, Luboinski B, et al; EORTC Head and Neck Cancer Cooperative Group. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of cancer phase III trial. J Natl Cancer Inst. 1996;88:890-899.
3. Parsons JT, Mendenhall WM, Stringer SP, et al. Squamous cell carcinoma of the oropharynx: surgery, radiation therapy, or both. Cancer. 2002;94:2967-2980.
4. Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French head and neck oncology and radiotherapy group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol. 2004;22:69-76.
5. Adelstein D, Li Y, Adams G, et al. An Intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21:92-98.
6. Pignon JP, Bourhis J, Domenge C, et al; MACH-NC Collaborative Group. Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: three meta-analyses of updated individual data. Lancet. 2000;355:949-955.
7. Bernier J, Schneider D. Cetuximab combined with radiotherapy: an alternative to chemoradiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck? Eur J Cancer. 2007;43:35-45.
8. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med. 2006;354: 567-578.
9. Cancer Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS. Available at: http://ctep.cancer.gov/ forms/CTCAEv3.pdf. Accessed August 9, 2006.
10. Forastiere AA, Burtness BA. Epidermal growth factor receptor inhibition in head and neck cancer-more insights, but more questions. J Clin Oncol. 2007;25:2152-2155.
11. Curran D, Giralt J, Harari P, et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol. 2007;25:2191-2197.
12. Forastiere AA, Goepfert H, Maor M. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349:2091-2098.
13. Peter RU, Beetz A, Ried C, et al. Increased expression of the epidermal growth factor receptor in human epidermal keratinocytes after exposure to ionizing radiation. Radiat Res. 1993;136:65-70.
14. Jost M, Kari C, Rodeck U. The EGF receptor-an essential regulator of multiple epidermal functions. Eur J Dermatol. 2000;10:505-510.
15. Elliott EA, Wright JR, Swan RS, et al. Phase III trial of an emulsion containing trolamine for the prevention of radiation dermatitis in patients with advanced squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Trial 99-13. J Clin Oncol. 2006;24:2092-2097.
16. Dörr W, Hendry JH. Consequential late effects in normal tissues. Radiother Oncol. 2001;61:223-231.
17. Denham JW, Peters LJ, Johansen J, et al. Do acute mucosal reactions lead to consequential late reactions in patients with head and neck cancer? Radiother Oncol. 1999;52:157-164.
18. Stone HB, Coleman CN, Anscher MS, et al. Effects of radiation on normal tissue: consequences and mechanisms. Lancet Oncol. 2003;4:529-536.
19. Trotti A, Klotch D, Endicott J, et al. Postoperative accelerated radiotherapy in high-risk squamous cell carcinoma of the head and neck: long term results of a prospective trial. Head Neck. 1998;20:119-123.
20. Weiss E, Himle P, Arnold-Bofinger H, et al. Therapeutic outcome and relation of acute and late side effects in the adjuvant radiotherapy of endometrial carcinoma stage I and II. Radiother Oncol. 1999;53:37-44.
21. Importance of overall treatment time for the outcome of radiotherapy in head and neck carcinoma: experience from the Danish Head and Neck Cancer Study. In: Proceedings of ICRO/OGRO 6; 6th International Meeting on "Progress in Radio-Oncology;" May 13-17, 1998; Salzburg, Austria.
22. Fowler JF, Lindstrom M. Loss of local control with prolongation in radiotherapy. Int J Radiat Oncol Biol Phys. 1992;23:457-467.
23. Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 1988;27:131-146.
24. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000;48:7-16.
25. Bourhis J, Lapeyre M, Tortochaux J, et al. Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial. J Clin Oncol. 2006;24:2873-2878.
26. Bernier J, Bonner J, Vermorken JB, et al. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol. 2008;19:142-149.
27. Budach W, Bölke E, Homey B. Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Med. 2007;357:514-515.
28. Bonner J, Ang K. More on severe cutaneous reaction with radiotherapy and cetuximab. N Engl J Med. 2007;357:1872.
29. Lord HK, Junor E, Ironside J. Cetuximab is effective, but more toxic than reported in the Bonner trial. Clin Oncol. 2008;20:96.
30. Lee N, Chuang C, Quivey J, et al. Skin toxicity because of intensitymodulated radiotherapy for head-and-neck carcinoma. Int J Radiat Oncol Biol Phys. 2002;53:630-637.
31. Caudell JJ, Sawrie SM, Spencer SA, et al. Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment. Int J Radiat Oncol Biol Phys. 2008;71:676-681.